Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Large language models can translate the archaic language of pharmacy prescriptions into plain English, but reducing medication errors for patients will require interventions that go further.
A pilot study suggests that the bispecific T cell engager blinatumomab may provide a new therapy for patients with refractory rheumatoid arthritis; larger studies and deep phenotyping will be crucial to thoroughly evaluate and optimize this approach.
The lay summary of trial results to be provided to participants should be written in plain language, use infographics and be concise — something that currently is almost never achieved.
The World Health Organization framework for tracking SARS-CoV-2 variants has been updated to reflect the continued evolution of the virus; this framework could be adapted for other emerging respiratory diseases with epidemic and pandemic potential.
A randomized controlled trial showed that following a personalized dietary program led to significant improvements in cardiometabolic and gut health as well as reductions in body weight compared to following standard dietary advice according to US Department of Agriculture guidelines.
Exome-sequencing analysis in a Chinese cohort of 1,578 children with cerebral palsy established a genetic etiology in 387 of the patients (24.5%). Children with cerebral palsy for whom perinatal asphyxia had been recorded at birth were found to be more likely to carry pathogenic or potentially pathogenic variants.
Growing interest in non-invasive brain–computer interfaces, rather than implants, might improve accessibility for patients, but resolution needs to be improved.
New data confirm that APOE4 homozygosity is a major genetic cause of Alzheimer’s disease, warranting the development of specialized research strategies, treatment approaches and clinical trials.
The study on APOE4 homozygosity indicates a genetic variant of Alzheimer’s disease with early symptom onset and distinct biomarker progression, highlighting the need for specialized treatment approaches.
In a tumor-agnostic phase 2 basket trial, the oral FGFR1–FGFR3 inhibitor pemigatinib elicits responses in tumor types beyond cholangiocarcinoma and bladder cancer and in tumor types with rarer FGFR alterations, with insights provided into resistance mechanisms.
Post hoc analysis of the DAPA-HF and DELIVER trials reports on the approach of win statistics to evaluate the effect of dapagliflozin on a hierarchical composite kidney outcome in patients with heart failure.
In a prospective study, a team-based approach combining continuous glucose monitoring with a technology-assisted remote patient monitoring program improved glycemia in a diverse cohort of children, adolescents and young adults with newly diagnosed type 1 diabetes.
Vision–language models can be trained to read cardiac ultrasound images with implications for improving clinical workflows, but additional development and validation will be required before such models can replace humans.
Using exome sequencing data from one of the largest cohorts of children with cerebral palsy, the genetic diagnostic rates of single-nucleotide and copy number variants were assessed and a sizeable fraction found to be clinically actionable.
A strategy that controls confounders in quantitative microbiome data challenges the validity of previously reported microbial markers in colorectal cancer and serves as a wake-up call for the microbiome research field.
The dynamics and durability of immune responses associated with protection against symptomatic infection in children offer insights to guide vaccination policies in pediatric populations.
In an open-label phase 2 trial, patients with non-small-cell lung cancer received neoadjuvant anti-PD-1 with or without anti-LAG-3, showing that curative intent surgery after combined blockade of PD-1 and LAG-3 is feasible, and leads to preliminary clinical responses.